Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer

NCT05826275 is registered in ClinicalTrials.gov with Toragen, Inc. as lead sponsor.

NCT NCT05826275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer
Lead sponsor
Toragen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 20, 2023
Completion date
June 28, 2025
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hpv associated cancers